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Abstract
Introduction Nipple aspiration is a noninvasive technique for
obtaining breast fluids from the duct openings of the nipple for
the evaluation of abnormalities associated with breast cancer.
Nipple aspirate fluid (NAF) can be elicited from 48 to 94% of
healthy women, and its production has been linked to an
increased relative risk for breast cancer development. NAF
production has been used in studies to guide the selection of
ducts for ductal lavage, a procedure in which ducts are
cannulated and flushed with saline to collect cells. In a previous
multicenter trial to evaluate intraductal approaches in women at
high-risk for breast cancer, NAF production was observed in
84% of the subjects. However, we observed a significantly
lower proportion of fluid-yielding subjects in a similar series of
high-risk women. The purpose of the present study was to
identify variables associated with this reduction.
Method Nipple aspiration was performed on 33 high-risk
women (defined as having a 5-year Gail model index of more
than 1.7, a personal or family history of breast cancer, and/or a
BRCA1 or BRCA2 germline mutation) to identify ductal orifices
for lavage procedures. Lavage was performed on all fluid-
yielding ducts and on nine non-fluid-yielding ducts.
Results Fluid-yielding ducts were identified in 12 of 33 (36%)
of the subjects in the present series, compared with 16 of 19
(84%) of the subjects undergoing identical procedures at our
facility during a multicenter trial (P  = 0.001). Reduced NAF
yields were associated with postmenopausal status (P = 0.02),
BRCA germline mutations (P  = 0.004), and risk reduction
therapies, including bilateral salpingo-oophorectomy (BSO)
and/or selective estrogen receptor modulators (SERMs; P =
0.009). All nine (100%) of the ductal lavage specimens
collected from non-fluidyielding ducts were acellular, in
comparison with 3 of 13 specimens from fluid-yielding ducts (P
< .001).
Conclusion Analysis of high-risk women in the present series
revealed patterns of reduced NAF production and ductal lavage
cellularity compared with a previous multicenter trial. The
present series included more BRCA-positive women, many of
whom had undergone BSO and/or were using SERMs. Our
data suggest that endocrine mechanisms associated with these
risk-reducing therapies may be related to patterns of diminished
breast fluid production.
Introduction
Nipple aspiration is a noninvasive suction technique used to
obtain breast fluid from the duct openings at the nipple. The
procedure elicits droplet formation from one or more ducts in
48 to 94% of healthy, nonlactating women, and these fluids
often contain exfoliated ductal epithelial cells [1-10]. The nip-
ple aspiration technique has been studied for several decades
as a potential screening tool to detect cytologic abnormalities
associated with proliferative breast lesions [1,5,7,11-13].
Long-term follow-up of women undergoing nipple aspiration
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revealed that the risk of developing breast cancer was twofold
to fivefold greater for women diagnosed with cytologic atypia
relative to those who did not yield any fluid [11-13]. Interest-
ingly, these studies revealed a continuum of relative risk that
was lowest for women who did not yield any fluid, higher for
women yielding acellular fluid, higher still for fluid-yielders with
normal or benign cells, and highest for fluid-yielders diagnosed
with atypia. Thus, the mere elicitation of acellular nipple aspi-
rate fluid (NAF) was associated with increased relative risk.
More recently the ductal lavage technique, which employs a
microcatheter to cannulate an individual duct opening and
flush the associated ductal system with saline, has been used
to collect higher numbers of exfoliated cells. In a multicenter
trial that we participated in to evaluate this approach, nipple
aspiration was performed on all subjects for the purpose of
locating fluid-yielding ducts (presumed to contain higher num-
bers of cells) before the lavage procedure [3]. Fluid-yielding
ducts were identified in 84% of the subjects overall, and in
84% of the trial subjects enrolled at our center. However, this
rate fell markedly to 36% (P = 0.001) when we performed the
procedure on a similar series of 33 high-risk women after the
conclusion of the trial. Here we present data suggesting that
the reduced NAF yields observed in the second series of sub-
jects may be related to the use of risk reduction therapies
including selective estrogen receptor modulators (SERMs;
tamoxifen and raloxifene) and/or oophorectomy.
Materials and methods
Participants
Subject participation for this study was approved by the Yale
Human Investigation Committee (protocol no. 11401), and
informed consent was obtained in all cases. Thirty-three high-
risk women (defined as women with a personal or family his-
tory of breast cancer, a 5-year Gail model index of more than
1.7, and/or a germline mutation in the breast cancer predispo-
sition gene BRCA1 or BRCA2), who were asymptomatic at
enrollment, were recruited through the Yale Cancer Center
Genetics Counseling Shared Resource and through referrals
from several regional breast clinical practices. The enrollment
criteria were identical to those of the multicenter trial that we
participated in, with the exception that women taking SERMs
were admitted to the present study, whereas they had been
excluded from the multicenter trial. To expand our analysis of
certain variables, we contacted all 19 of the multicenter trial
subjects who had participated at our center by letter to
request oophorectomy history, which had not been collected
at the time of the trial. We received responses from 10 sub-
jects, all of whom are included in a subset of the analyses in
this report.
Nipple aspiration and ductal lavage
Each nipple was cleansed with Nuprep exfoliant (DO Weaver
& Co., Aurora, CO), and then subjected to nipple aspiration
using a FirstCyte™ Aspirator (Cytyc Corporation, Boxborough,
MA) to identify the location of fluid-producing duct orifices. A
subject was classified as a fluid yielder if one or more drops of
fluid were obtained from one or more ducts. Each productive
duct was cannulated with a FirstCyte™ DL Catheter (Cytyc
Corporation) and lavaged with 10 to 20 ml of sterile saline
(0.9% sodium chloride, Inj., USP; Abbott Laboratories, North
Chicago, IL). In addition, nine non-fluid-yielding ducts were
cannulated and lavaged.
Cytology
Cytomorphologic evaluation was performed by a board-certi-
fied cytopathologist (DLR) specifically trained in ductal lavage
interpretation. Specifically, lavage samples were graded on a
four-point scale on the basis of the epithelial cell morphology
(benign, mildly atypical, markedly atypical, and malignant).
Specimens lacking sufficient epithelial cells for classification
were categorized as ICMD (insufficient cells to make a
diagnosis).
Statistics
Frequencies were compared using the two-tailed Fisher exact
test and the χ2 test. The proportions of fluid-yielding women
were compared as follows: first, between the multicenter trial
and the present series of 33 subjects; second, between sub-
sets of the 33 subjects in the present series; and third,
between subsets of the pooled group of 43 subjects.
Table 1
Proportion of subjects with ducts yielding nipple aspirate fluid 
in multicenter trial and present study
Group NAF+ women (%) P
Multicenter trial 
(n = 507)
Post-trial series 
(n = 33)
Overall 427/507 (84)
Yale trial site 16/19 (84) 12/33 (36) 0.001
Premenopausal 204/227 (90) 7/10 (70)
Postmenopausal 209/268 (78) 5/23 (22) <0.001
P < 0.001 P = 0.02
No risk reduction ND 8/11 (73)
Risk reduction ND 5/22 (23)
P = 0.009
BRCA- ND 11/17 (65)
BRCA+ ND 2/16 (13)
P = 0. 004
The P values in the right hand column reflect comparisons between 
the multicenter trial and the present series. The P values listed in the 
two center columns reflect comparisons between the two groups 
listed immediately above them. NAF, nipple aspirate fluid; ND, not 
done.Available online http://breast-cancer-research.com/content/7/6/R1017
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Results
In the present series, the overall proportion of women with
fluid-yielding ducts was 12 of 33 (36%), compared with 427
of 507 (84%) for the multicenter trial at large, and 16 of 19
(84%) for the Yale trial site (P = 0.001; Table 1). The women
in the present series underwent identical procedures adminis-
tered at the same facility as the subjects who had participated
at the Yale trial site. Table 2 compares the characteristics of
the 33 participants enrolled in the present study with those of
the multicenter trial. The subjects were similar in most
respects, with the exception of BRCA1/2 germline mutation
and risk reduction therapy status. In the multicenter trial, fewer
than 1% of the women were BRCA-positive, whereas in the
present trial 16 of 33 (48.5%) of the subjects had BRCA
germline mutations (P < 0.001). Another difference is that the
multicenter trial excluded women who were taking SERMs,
whereas in the current study, 12 of 33 (36.4%) of the partici-
pants were taking SERMs (tamoxifen or raloxifene; P < 0.001).
There was also a higher, but statistically insignificant, propor-
tion of postmenopausal women in the present series (P  <
0.10). A substantial number of these women (7 of 23) had
undergone surgically induced menopause before the age of
49 years as the result of bilateral salpingo-oophorectomy
(BSO). The proportion of women in the multicenter trial who
had undergone oophorectomy was not documented. Two of
the 10 trial participants who responded to our letters reported
a history of oophorectomy at the time of trial enrollment. Five
women in the present series were employing both forms of risk
reduction at the time of study enrollment.
Within the present series of 33 subjects, NAF production var-
ied according to menopausal status, BRCA mutation status,
and risk reduction status (Table 1). NAF was elicited in 5 of 23
(22%) postmenopausal versus 7 of 10 (70%) premenopausal
women (P = 0.02), and in 11 of 17 (65%) BRCA-negative
women versus 2 of 16 (13%) of BRCA-positive women (P =
0.004). Fluid-yielding ducts were identified in 8 of 11 (73%)
women not employing any form of risk reduction, versus 5 of
22 (23%) women who had undergone oophorectomy and/or
were taking SERMs at the time of enrollment into the study (P
= 0.009). To study the independent contributions of these var-
iables to NAF reduction, we performed a set of analyses on a
pooled set of subjects including the 33 subjects from the
present series plus a subset of the multicenter trial subjects for
whom we had retrospectively obtained oophorectomy status.
To separate the contributions of age, menopause and
Table 2
Comparison between characteristics of women enrolled in the multicenter trial and the present study
Characteristic Average, number, or % (range or proportion) P
Multicenter trial Post-trial series
Age (years) 51.9 (26–81) 48.4 (31–67)
Age at menarche (years) 12.6 (7–25) 12.7 (9–17)
Age at first birth (years) 25.3 (14–42) 28.4 (18–39)
Menopausal status Unknown for 2%
Premenopausal 45 (227/507) 30.3 (10/33)
Postmenopausal 53 (268/507) 69.7 (23/33)
1st-degree relatives with breast cancer 0.5 (0–5) 0.74 (0–3)
No. of previous biopsies 1.7 (0–18) 1.1 (0–4)
Women with previous atypia (%) 19 (96/507) 10 (3/30)
Women with previous breast cancer (%) 57 (291/507) 45 (15/33)
BRCA+ women (%) <1 (3/507) 48.5 (16/33) <0.001
Women taking SERMs (%) 0 36.4 (12/33) <0.001
Women with oophorectomy (%) Unknowna 51.5 (17/33)
Racial heritage
White 84 100
African-American 12 0
Asian 2 0
Other 2 0
aOophorectomy history was not recorded during the trial, but was determined retrospectively for 10 of 19 subjects who participated at our site.
P values reflecting insignificant associations are not shown. SERM, selective estrogen receptor modulator.Breast Cancer Research    Vol 7 No 6    Higgins et al.
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surgically induced menopause resulting from oophorectomy,
we first stratified the 43 women into two groups: those aged
49 years and below, and those aged 50 years and above. NAF
production within each group was then analyzed as a function
of  BRCA mutation or risk reduction therapy status. These
comparisons are shown in Table 3 and reveal a significantly
lower proportion of fluid-yielders in association with BRCA
germline mutations (P = 0.008) and risk reduction strategies
(P = 0.0003) among women below the age of 50 years. When
BRCA-negative women above and below the age of 50 years
were considered separately, there were significantly lower
proportions of fluid-yielders among the women on risk reduc-
tion therapy (P = 0.03, P = 0.045). No significant association
was observed between NAF production and previous breast
cancer history (P = 0.468).
In the multicenter ductal lavage trial [3] only NAF-yielding
ducts were lavaged, in accordance with the rationale that pro-
ductive ducts would be more likely to contain large numbers of
cells. In this study the same protocol was followed, but lavage
was also performed on nine subjects who did not yield fluid; all
nine of these lavage specimens were classified as ICMD. Of
the 22 lavage specimens collected in this series, 4 of 22
(18%) were classified as mildy atypical, 5 of 22 (23%) as
benign, and 13 of 22 (54%) as ICMD. ICMD was observed in
nine of nine non-fluid-yielding ducts versus 3 of 13 (59%) fluid-
yielding ducts (P = 0.00046). The proportion of ICMD in the
multicenter trial was 84 of 383 (22%) [3].
Discussion
The overall percentage of fluid-yielding subjects in the present
series (36%) was relatively low in comparison with those
reported in other studies (48 to 94%) [1-3,5-10,14] and at our
site during the multicenter trial (84%) [3]. Reduced NAF pro-
duction has consistently been associated with postmenopau-
sal status and/or increasing age in other studies
[1,3,10,15,16]. In the multicenter trial, fluid-yielding ducts
were observed in 90% of the premenopausal women, com-
pared with 78% of the postmenopausal women (P < 0.001)
[3]. In the present study, NAF-yielding ducts were identified in
only 22% of the postmenopausal women. The marked differ-
ence between these similar high-risk postmenopausal groups
(P < 0.001) suggests that the overall decline observed in the
present series is associated with additional variables. The sub-
ject population in the present study differed in having more
women with BRCA germline mutations, many of whom had
undergone BSO and/or were using SERMs. Seven of 23 post-
menopausal women in this series were less than 49 years old
and had undergone surgically induced menopause as the
result of BSO. When NAF production was analyzed among
the 33 subjects in relation to these variables, we found it to be
significantly reduced in association with BRCA mutations and
risk reduction therapies (Table 3). Additional analyses
revealed lower NAF production in association with risk-reduc-
ing therapies in BRCA-negative women (P = 0.045) and a
similar, but insignificant, trend for BRCA-positive women.
Although NAF and ductal lavage have been evaluated in
women at high risk for breast cancer development, there have
been only a handful of studies describing the application of
intraductal approaches to high-risk women with BRCA germ-
line mutations [17,18]. The largest study, conducted by Kurian
and colleagues [18], included 75 women with high inherited
risk, 56 of whom had BRCA1/2 mutations. The overall NAF
rate in this study was 48%. Although no direct correlation
between fluid production and risk reduction therapies was
observed, there were significantly fewer fluid-yielding subjects
among women with a previous history of breast or ovarian can-
cer. The authors suggested therapy-related anti-hormonal
mechanisms including chemotherapy-induced amenorrhea as
possible explanations for the trend. Mitchell and colleagues,
Table 3
Proportions of women with fluid-yielding ducts within the 
pooled group of 43 subjects
Subjects NAF+ women P
Proportion %
Women <50 years old (n = 22)
No risk reduction 11/12 92
Risk reduction 1/10 10 0.0003
BRCA- 10/12 83
BRCA+ 2/10 20 0.008
BRCA- women (n = 12)
No risk reduction 9/9 100
Risk reduction 1/3 33 0.045
BRCA+ women (n = 10)
No risk reduction 2/3 66
Risk reduction 0/7 0 0.07
Women ≥50 years old (n = 21)
No risk reduction 6/7 86
Risk reduction 4/14 29 0.02
BRCA- 9/14 64
BRCA+ 1/7 14 0.06
BRCA- women (n = 14)
No risk reduction 6/6 100
Risk reduction 3/8 38 0.03
BRCA+ women (n = 7)
No risk reduction 0/1 0
Risk reduction 1/6 17 1.000
NAF, nipple aspirate fluid.Available online http://breast-cancer-research.com/content/7/6/R1017
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who performed intraductal approaches on a series of 52
women with germline BRCA1/2 mutations, observed NAF
production in 60% of all subjects (Mitchell G personal commu-
nication). Although no correlation between NAF production
and previous cancer was noted in this study, significantly
reduced levels of NAF secretion and ductal lavage cellularity
were seen in association with natural and surgically induced
menopause. Although we cannulated and lavaged only nine
dry ducts, all of them were also characterized as acellular.
Kurian and colleagues [18] also reported higher rates of ICMD
in association with previous breast or ovarian cancer, chemo-
therapy, and SERM usage.
The risk-reducing benefits of SERMs and oophorectomy for
breast cancer patients and women at high risk for breast can-
cer are well documented. Clinical trials have demonstrated
that tamoxifen significantly decreases recurrence rates in
breast cancer patients and markedly reduces the incidence of
invasive and noninvasive breast cancer development in high-
risk women [19-26]. Breast cancer risk reduction has also
been observed in postmenopausal women undergoing treat-
ment with raloxifene for osteoporosis [27]. Similarly, ovarian
ablation has been shown to reduce recurrence and mortality in
breast cancer patients [23,24,28,29], and prophylactic
oophorectomy has been shown to significantly reduce breast
cancer incidence in high-risk women, including BRCA1 and
BRCA2 mutation carriers [30-33]. Our series included eight
BRCA1 mutation carriers, and although most BRCA1 tumors
are estrogen receptor negative, both oophorectomy and
tamoxifen have been shown to protect against the develop-
ment or recurrence of breast cancer in this group
[24,25,30,32,33].
The biologic regulation and significance of breast duct fluid
production in nonlactating women are not currently under-
stood. Our data showing that risk reduction therapies are
associated with diminished breast fluid secretion complement
previous epidemiologic studies showing that NAF production
is linked to increased relative risk for breast cancer develop-
ment [11-13]. The fact that NAF is reduced in association with
therapies that eliminate or block ovarian steroids suggests that
the relationship between risk and breast fluid production is
related to hormones. Although SERMs modulate the actions of
estrogens, we did not analyze the relationship of NAF to
SERMs and BSO separately. We therefore cannot speculate
on the relative contributions of estrogens and progesterone to
the observed effect. However, earlier studies did not find asso-
ciations between serum estrogen levels and NAF production
[9,10,34]. One of these studies reported an association
between NAF production and breast fluid prolactin levels, but
not estrogen levels [34]. It is possible that the relationship
between NAF production and ovarian hormones involves indi-
rect systemic and/or paracrine mechanisms.
Because NAF production and cytologic atypia are both asso-
ciated with increased relative risk for breast cancer develop-
ment, it is tempting to speculate that NAFs reflect the
secretory activity of proliferative ductal epithelial cells. How-
ever, several recent studies have generated paradoxical
results concerning the relationship between breast fluid, cyto-
logic atypia, and breast cancer risk. These studies have
revealed the presence of cytologic atypia in non-fluid-yielding
ducts and in NAF-negative women [9,17,18,35]. Although
seemingly at odds with the body of data on NAF, the atypical
epithelial cells associated with non-fluid-yielding ducts may
constitute biologically distinct variants and may hold clues for
stratifying the prognostic significance of atypia. Our data sug-
gest that reduced NAF production reflects lower endogenous
hormone levels and therefore that atypical cells proliferating in
non-fluid yielding ducts may represent hormone-independent
variants. Kurian and colleagues suggested the possibility that
women with atypia in non-fluid-yielding ducts might be at
higher risk for developing estrogen-receptor-negative tumors
[18].
Conclusion
An analysis of high-risk women in the present series revealed
patterns of reduced NAF production and ductal lavage cellu-
larity in comparison with a previous multicenter trial. The
present series included more BRCA-positive women, many of
whom had undergone BSO and/or were using SERMs. Our
data suggest that endocrine mechanisms associated with
these risk-reducing therapies may be related to patterns of
diminished breast fluid production. Although NAF production
does not seem to be obligatorily linked to cytologic atypia, it
may be a general indicator of endogenous reproductive hor-
mone levels that are widely implicated in breast cancer devel-
opment. More importantly, NAF seems to reflect the impact of
the systemic hormonal milieu on the breast tissue itself. Thus,
its production during the NAF procedure could potentially pro-
vide additional information to a woman's risk profile, and could
serve as a valuable endpoint in chemoprevention trials.
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